Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 9/20 | 0.36 |
| ▸ | AGXT | P21549 | 3/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | PGK1 | P00558 | 1/20 | 0.32 |
| ▸ | PGK2 | P07205 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5473625 | 0.80 | NPSR1 (0.40) | KCNH2NOS1NOS2NPSR1 | |
| SCHEMBL27800462 | 0.78 | KCNH2 (0.41) | KCNH2NOS1NOS2NPSR1BACE1 | |
| SCHEMBL4049049 | 0.78 | KCNH2 (0.41) | KCNH2NOS1NOS2NPSR1PGK1 | |
| SCHEMBL4047122 | 0.78 | KCNH2 (0.46) | KCNH2NOS1NOS2NPSR1BACE1 | |
| SCHEMBL9977688 | 0.76 | SMN1; SMN2 (0.42) | KCNH2NOS1NOS2ADORA2A | |
| SCHEMBL4047727 | 0.74 | KCNH2 (0.40) | KCNH2 | |
| SCHEMBL24618108 | 0.74 | HRH1 (0.42) | KCNH2NOS1NOS2NPSR1BACE1 | |
| SCHEMBL3511340 | 0.74 | HTR7 (0.41) | KCNH2NOS1NOS2NPSR1BACE1 | |
| SCHEMBL12710391 | 0.74 | KCNH2 (0.37) | KCNH2NOS1NOS2NPSR1BACE1 | |
| SCHEMBL29792017 | 0.74 | HRH1 (0.42) | KCNH2NOS1NOS2NPSR1BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070042975-A1 | Novel indolopyrrolocarbazole derivative with antitumor activity | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| EP-1666485-A1 | NOVEL INDOLOPYRROLOCARBAZOLE DERIVATIVE WITH ANTITUMOR ACTIVITY | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070042975-A1 | Novel indolopyrrolocarbazole derivative with antitumor activity | HK1, G6PD, HK2 | KCNH2 325/4885NOS1 2077/4885NOS2 2262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.